Market LIVE
Published markets; coverage varies by country
Product profile · United States

LYRICA CR

 ·  Patent Litigation & Settlement History ↓

IngredientPREGABALIN
Application typeNDA
Application209501
Product003
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength330MG
Approval date2017-10-11
Marketing statusPrescription
Status event—
ApplicantUPJOHN
Product source

Current GenericRadar decision

Year2021
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2021-04-13
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2021-04-13
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
100224472026-11-02U U-2136———
———
100224472026-11-02U U-2137———
———
89456202026-11-02DP/U U-2137———
———
89456202026-11-02DP/U U-2136———
———
91445592026-11-02DP ————
———
100224472027-05-02— ————
—2027-05-02—
89456202027-05-02— ————
—2027-05-02—
91445592027-05-02— ————
—2027-05-02—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211593 / 003FINAL_APPROVAL · FINAL_APPROVED2021-04-13—ALVOGEN INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211889 / 003FINAL_APPROVAL · FINAL_APPROVED2021-04-13—SUN PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213226 / 003FINAL_APPROVAL · FINAL_APPROVED2021-04-13—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213313 / 002FINAL_APPROVAL · FINAL_APPROVED2021-04-13—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211431 / 001FINAL_APPROVAL · FINAL_APPROVED2021-07-02—PHARMOBEDIENT CONSULTING LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211687 / 003FINAL_APPROVAL · FINAL_APPROVED2021-07-06—ALVOGEN MALTA OPERATIONS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215249 / 003FINAL_APPROVAL · FINAL_APPROVED2022-03-22—RUBICON RESEARCH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215577 / 003FINAL_APPROVAL · FINAL_APPROVED2022-08-26—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215675 / 003FINAL_APPROVAL · FINAL_APPROVED2022-09-14—SCIEGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214496 / 003FINAL_APPROVAL · FINAL_APPROVED2023-06-01—EPIC PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217857 / 001FINAL_APPROVAL · FINAL_APPROVED2025-01-28—AIPING PHARMACEUTICAL INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 11 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211593 / 003ALVOGEN INCFINAL_APPROVAL · FINAL_APPROVED2021-04-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211889 / 003SUN PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2021-04-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213226 / 003MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2021-04-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213313 / 002APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2021-04-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211431 / 001PHARMOBEDIENT CONSULTING LLCFINAL_APPROVAL · FINAL_APPROVED2021-07-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211687 / 003ALVOGEN MALTA OPERATIONS LTDFINAL_APPROVAL · FINAL_APPROVED2021-07-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215249 / 003RUBICON RESEARCH LTDFINAL_APPROVAL · FINAL_APPROVED2022-03-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215577 / 003ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2022-08-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215675 / 003SCIEGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2022-09-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214496 / 003EPIC PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2023-06-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217857 / 001AIPING PHARMACEUTICAL INCFINAL_APPROVAL · FINAL_APPROVED2025-01-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2021-04-13TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.